Bioxyne

AGM Presentation

2.30pm.,November 29th 2012
33 Erskine St, Sydney.

Disclaimer

This presentation is given:

- for the sole purpose of providing the recipients with background information about Bioxyne's business.
- Does not constitute an offer, invitation or recommendation to subscribe for or purchase any security in Bioxyne and does not form the basis of any contract or commitment.

No representation express or implied is made to the fairness, accuracy, completeness or correctness of information contained in this presentation, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in the presentation ("forward looking statements"). Forward looking statements are by their nature subject to significant uncertainties and contingencies and are based upon a number of estimates and assumptions that are subject to change (and in many cases outside the control of Bxn and its directors) which may cause the actual results of Bxn to be materially different from any future results or performance expressed or implied by such forward looking statements.

To the extent permitted by law, neither Bxn nor its related corporations, directors, employees or agents, nor any other person accepts any liability including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it.

You represent and confirm that by attending and/or retaining this presentation, that you accept the above conditions.

Agenda

- Chairman's address
- Managing Director Review
- Shareholder Resolutions

Process

1. Motions will be called by the Chair – a seconder will then be called
   - A mover or seconder can't move an amendment
   - Motion fails if it does not pose a matter for decision

2. Motion discussed (Q from floor and A by mover/ seconder)
   - Time limit for speaking on a motion is four minutes unless the Chairman rules otherwise
   - Discussion of a motion will be limited to the subject matter of the motion

Process-II

A scrutineer has been appointed - instruments appointing representatives are available for inspection

The attendance register is available for signature

Notice of Meeting – mailed to members and, absent objection, will be taken as having been read

Quorum is two members

No absent member has submitted an apology

The minutes of the last meeting of shareholders are available

Bioxyne

Managing Director's Presentation

Summary

- A year of transition
- ASX Listed - April 2012
- Clinical Study Results June 2012
- Heads of Agreement with Vaxine Pty Ltd
- Restructured Board of Directors
- Shareholders to vote on future direction

Options available to the Company in June

- The Board assessed the following options
  - Development of the probiotics business
  - Sales of HI 164 as an OTC product
  - Merging with an alternative technology
  - Further study into HI 164 in selected patients
  - Market opportunity assessment
- Board approval to conduct market assessment
- Continued evaluation of new opportunities

Market Assessment

- Conducted by Torreya Partners (US based)
- 15 potential partners identified
- Opportunity to engage with clear datasets/indications
- Supported a further study
- Torreya Partners engagement is now complete

Proposed Study Partners-Vaxine Pty Ltd

- Internationally recognised experts in vaccine development
- Experienced with large studies
- First company in the world to undertake Swine flu vaccine study
- Proven entrepreneurial approach to product development
- Commercial and research partners include National Institute of Health (USA)

Proposed Study Design

- Based on analyses of Studies 002/4/5
- HI-H002 and HI-H004 indicated potential benefits of HI 164 in patients producing “copious amounts of sputum”
- Study HI-H005 demonstrated reduced number of patients with copious sputum production compared to previous studies(34% v’s 62%) and lower initial H.influenzae infection rates (5% v’s 37%)
- Proposed Study HI-H007 in conjunction with a leading S.Australian medical centre.

Potential benefits in targeted group









Clear separation for treated v's untreated responses to HI 164 across "All Ages", "<65y.o", "<70y.o. and "<75y.o." when analysis looks at sputum producing patients upon presentation.

Study Criteria-What changes ?

- Targeted/Defined patient group
- Study matches feedback from a “Big Pharma” requirement
- Focused study with local professional management
- Mitigation of seasonal risk
- Parallel mode of action studies

Study Funding

- Value of study $3.4m
- Achieved through
  - Sale of equity
  - Sale of Probiotics business
  - Secured Convertible Note
- Risk-Reward
  - 10% of gross revenues received upon commercialization

Further business opportunities

- Objectives
  - Build a portfolio of complementary assets in BXN
  - May include devices or pharma products
  - Several opportunities identified
- Timeframes
  - In parallel with Study HI-H007
  - Targeted build out by mid 2014

Proposed Road Map Forward



Targeted Company Portfolio-2014

Asset	Phase 1	Phase 2	Phase 3	Comments
HI 164				Pending shareholder approval to proceed with further study.
Asset 1				Ideally a device/ product that can be commercialised short term.
Asset 2				
Asset 3				

EGM

- Shareholders to vote on the future direction of the Company
- Either
  - HI 164 study with a supporting capital raise, or
  - A future with other technologies
- EGM targeted for late 2012/early 2013


Bioxyne